The DOI matches its Crossref record; 346 of the 346 references it cites were found in a registry or an index.
Breast Cancer Treatments: Updates and New Challenges
Open accessAbstract
Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B, HER2 and triple-negative breast cancer (TNBC)) according to the expression of the estrogen receptor (ER) and the progesterone receptor (PR), and the overexpression of the human epidermal growth factor receptor 2 (HER2). Current BC treatments target these receptors (endocrine and anti-HER2 therapies) as a personalized treatment. Along with chemotherapy and radiotherapy, these therapies can have severe adverse effects and patients can develop resistance to these agents. Moreover, TNBC do not have standardized treatments. Hence, a deeper understanding of the development of new treatments that are more specific and effective in treating each BC subgroup is key. New approaches have recently emerged such as immunotherapy, conjugated antibodies, and targeting other metabolic pathways. This review summarizes current BC treatments and explores the new treatment strategies from a personalized therapy perspective and the resulting challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–346 of 346
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
Perez, E. A., Suman, V. J., Davidson, N. E., Gralow, J. R., Kaufman, P. A., Visscher, D. W., Chen, B., Ingle, J. N., Dakhil, S. R., Zujewski, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7045 · Cited by 255
Blancher, C., Moore, J. W., Talks, K., Houlbrook, S., & Harris, A. L. (2000) · PubMed · Cited by 255
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 254
Luminal A Breast Cancer and Molecular Assays: A Review
Gao, J. J., & Swain, S. M. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0535 · Cited by 254
Davis, N. M., Sokolosky, M., Stadelman, K., Abrams, S. L., Libra, M., Candido, S., Nicoletti, F., Polesel, J., Maestro, R., D’Assoro, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2209 · Cited by 250
Mittendorf, E. A., Clifton, G. T., Holmes, J. P., Schneble, E., van Echo, D., Ponniah, S., & Peoples, G. E. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu211 · Cited by 248
Triple-negative breast cancer: recent treatment advances
Bergin, A. R. T., & Loi, S. (2019) · F1000Research · doi:10.12688/f1000research.18888.1 · Cited by 248
Kamath, K., Wilson, L., Cabral, F., & Jordan, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414477200 · Cited by 247
Cell killing by antibody–drug conjugates
Kovtun, Y. V., & Goldmacher, V. S. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.010 · Cited by 246
Swain, S. M., Ewer, M. S., Viale, G., Delaloge, S., Ferrero, J.-M., Verrill, M., Colomer, R., Vieira, C., Werner, T. L., Douthwaite, H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx773 · Cited by 244
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 240
Engstrøm, M. J., Opdahl, S., Hagen, A. I., Romundstad, P. R., Akslen, L. A., Haugen, O. A., Vatten, L. J., & Bofin, A. M. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2647-2 · Cited by 238
Human Aromatase: cDNA Cloning, Southern Blot Analysis, and Assignment of the Gene to Chromosome 15
CHEN, S., BESMAN, M. J., SPARKES, R. S., ZOLLMAN, S., KLISAK, I., MOHANDAS, T., HALL, P. F., & SHIVELY, J. E. (1988) · DNA · doi:10.1089/dna.1988.7.27 · Cited by 231
Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp304 · Cited by 231
Jones, R. H., Casbard, A., Carucci, M., Cox, C., Butler, R., Alchami, F., Madden, T.-A., Bale, C., Bezecny, P., Joffe, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30817-4 · Cited by 229
Li, X., Yang, C., Wan, H., Zhang, G., Feng, J., Zhang, L., Chen, X., Zhong, D., Lou, L., Tao, W., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.01.021 · Cited by 227
Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx002 · Cited by 226
Human TROP-2 is a tumor-associated calcium signal transducer
Rapani, E., Sacchetti, A., Corda, D., & Alberti, S. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980529)76:5<671::aid-ijc10>3.0.co;2-7 · Cited by 220
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents
Fojo, T., & Menefee, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm172 · Cited by 217
Molecular classification of breast cancer: A retrospective cohort study
Al-thoubaity, F. K. (2020) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2019.11.021 · Cited by 215
Novel antioestrogens without partial agonist activity
Wakeling, A. E., & Bowler, J. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90014-3 · Cited by 214
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer
Nunnery, S. E., & Mayer, I. A. (2020) · Drugs · doi:10.1007/s40265-020-01394-w · Cited by 212
AKT crystal structure and AKT-specific inhibitors
Kumar, C. C., & Madison, V. (2005) · Oncogene · doi:10.1038/sj.onc.1209087 · Cited by 206
Cardiac Side-effects From Breast Cancer Radiotherapy
Taylor, C. W., & Kirby, A. M. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.06.007 · Cited by 205
Mustacchi, G., Ceccherini, R., Milani, S., Pluchinotta, A., De Matteis, A., Maiorino, L., Farris, A., Scanni, A., & Sasso, F. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg117 · Cited by 202
Method for grading breast cancer.
Elston, E. W., & Ellis, I. O. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.2.189-b · Cited by 201
Pyrotinib: First Global Approval
Blair, H. A. (2018) · Drugs · doi:10.1007/s40265-018-0997-0 · Cited by 201
Hennigs, A., Riedel, F., Gondos, A., Sinn, P., Schirmacher, P., Marmé, F., Jäger, D., Kauczor, H.-U., Stieber, A., Lindel, K., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2766-3 · Cited by 199
PD-1/PD-L1 Pathway in Breast Cancer
Schütz, F., Stefanovic, S., Mayer, L., von Au, A., Domschke, C., & Sohn, C. (2017) · Oncology Research and Treatment · doi:10.1159/000464353 · Cited by 196
Han, H. S., Diéras, V., Robson, M., Palácová, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D., Campone, M., Telli, M. L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx505 · Cited by 194
Kornblum, N., Zhao, F., Manola, J., Klein, P., Ramaswamy, B., Brufsky, A., Stella, P. J., Burnette, B., Telli, M., Makower, D. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9331 · Cited by 189
Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
Chen, H., Wu, J., Zhang, Z., Tang, Y., Li, X., Liu, S., Cao, S., & Li, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00909 · Cited by 188
Xuhong, J., Qi, X., Zhang, Y., & Jiang, J. (2019) · PubMed · Cited by 187
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., Singer, C. F., Lowe, E. S., Watkins, C. L., & Carmichael, J. (2013) · Breast Cancer Research · doi:10.1186/bcr3484 · Cited by 184
Lee, J.-M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L., Zujewski, J. A., Yu, M., Gordon, N., Ji, J., Sissung, T. M., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju089 · Cited by 184
Martín, M., Chan, A., Dirix, L., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180
Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquiere, N., Bradley, E., Bull, R., Do, S., Dotson, J., Dudley, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 179
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2 -Amplified Gastric Cancer Cells
Chen, C.-T., Kim, H., Liska, D., Gao, S., Christensen, J. G., & Weiser, M. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0754 · Cited by 178
Balmaña, J., Tung, N. M., Isakoff, S. J., Graña, B., Ryan, P. D., Saura, C., Lowe, E. S., Frewer, P., Winer, E., Baselga, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu187 · Cited by 177
Zhang, Y., Moerkens, M., Ramaiahgari, S., de Bont, H., Price, L., Meerman, J., & van de Water, B. (2011) · Breast Cancer Research · doi:10.1186/bcr2883 · Cited by 171
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
Beeram, M., Tan, Q.-T. N., Tekmal, R. R., Russell, D., Middleton, A., & deGraffenried, L. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm170 · Cited by 170
Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer.
Gazet, J. C., Ford, H. T., Coombes, R. C., Bland, J. M., Sutcliffe, R. P., Quilliam, J., & Lowndes, S. (1994) · PubMed · Cited by 167
Lagadec, C., Vlashi, E., Della Donna, L., Meng, Y., Dekmezian, C., Kim, K., & Pajonk, F. (2010) · Breast Cancer Research · doi:10.1186/bcr2479 · Cited by 167
Balasubramaniam, S., Beaver, J. A., Horton, S., Fernandes, L. L., Tang, S., Horne, H. N., Liu, J., Liu, C., Schrieber, S. J., Yu, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1337 · Cited by 167
Pertuzumab: new hope for patients with HER2-positive breast cancer
Capelan, M., Pugliano, L., De Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C., Loi, S., & Piccart-Gebhart, M. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds328 · Cited by 166
André, F., Hurvitz, S., Fasolo, A., Tseng, L.-M., Jerusalem, G., Wilks, S., O’Regan, R., Isaacs, C., Toi, M., Burris, H. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9161 · Cited by 166
Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
Ribatti, D., Nico, B., Ruggieri, S., Tamma, R., Simone, G., & Mangia, A. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.07.002 · Cited by 166
Brufsky, A. M., & Dickler, M. N. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0423 · Cited by 165
Mechanisms of lapatinib resistance in HER2-driven breast cancer
D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., & Bianco, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.08.001 · Cited by 164
Dokter, W., Ubink, R., van der Lee, M., van der Vleuten, M., van Achterberg, T., Jacobs, D., Loosveld, E., van den Dobbelsteen, D., Egging, D., Mattaar, E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0040-t · Cited by 163
Drew, Y., Ledermann, J., Hall, G., Rea, D., Glasspool, R., Highley, M., Jayson, G., Sludden, J., Murray, J., Jamieson, D., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.41 · Cited by 162
Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
Szostakowska, M., Trębińska-Stryjewska, A., Grzybowska, E. A., & Fabisiewicz, A. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5023-4 · Cited by 161
Bachelot, T., Filleron, T., Bieche, I., Arnedos, M., Campone, M., Dalenc, F., Coussy, F., Sablin, M.-P., Debled, M., Lefeuvre-Plesse, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01189-2 · Cited by 161
TAYLOR, K. M., MORGAN, H. E., JOHNSON, A., HADLEY, L. J., & NICHOLSON, R. I. (2003) · Biochemical Journal · doi:10.1042/bj20030478 · Cited by 160
Borges, V. F., Ferrario, C., Aucoin, N., Falkson, C., Khan, Q., Krop, I., Welch, S., Conlin, A., Chaves, J., Bedard, P. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1812 · Cited by 160
Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling
Barone, I., Brusco, L., & Fuqua, S. A. W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1753 · Cited by 159
Sharma, D., Blum, J., Yang, X., Beaulieu, N., MacLeod, A. R., & Davidson, N. E. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0011 · Cited by 158
Jovanović, B., Mayer, I. A., Mayer, E. L., Abramson, V. G., Bardia, A., Sanders, M. E., Kuba, M. G., Estrada, M. V., Beeler, J. S., Shaver, T. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3055 · Cited by 156
Oliveira, M., Saura, C., Nuciforo, P. G., Calvo, I., Andersen, J., Passos‐Coelho, J. L., Gil, M. G., Bermejo, B., Patt, D. A., Ciruelos, E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz177 · Cited by 156
Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer.
Robertson, J. F. R., Todd, J. H., Ellis, I. O., Elston, C. W., & Blamey, R. W. (1988) · BMJ · doi:10.1136/bmj.297.6647.511 · Cited by 153
Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies
He, M. Y., Rancoule, C., Rehailia-Blanchard, A., Espenel, S., Trone, J., Bernichon, E., Guillaume, E., Vallard, A., & Magné, N. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.004 · Cited by 153
Jain, S., Shah, A. N., Santa-Maria, C. A., Siziopikou, K. P., RADEMAKER, A. W., Helenowski, I., Cristofanilli, M., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4792-0 · Cited by 152
HER2-positive breast cancer: Current and new therapeutic strategies
Escrivá-de-Romaní, S., Arumí, M., Bellet, M., & Saura, C. (2018) · The Breast · doi:10.1016/j.breast.2018.03.006 · Cited by 150
Penel, N., Adenis, A., & Bocci, G. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.009 · Cited by 149
Secondary mutations of BRCA1/2 and drug resistance
Dhillon, K. K., Swisher, E. M., & Taniguchi, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01840.x · Cited by 148
Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
Krishnamachary, B., Penet, M., Nimmagadda, S., Mironchik, Y., Raman, V., Solaiyappan, M., Semenza, G. L., Pomper, M. G., & Bhujwalla, Z. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044078 · Cited by 145
Trail, P. A., Dubowchik, G. M., & Lowinger, T. B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.013 · Cited by 142
Guan, Z., Xu, B., DeSilvio, M., Shen, Z., Arpornwirat, W., Tong, Z., Lorvidhaya, V., Jiang, Z., Yang, J., Makhson, A. N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5241 · Cited by 141
Baselga, J. M., Dent, S. F., Cortés, J., Im, Y., Dieras, V. C., Harbeck, N., Krop, I. E., Verma, S., Wilson, T. R., Jin, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1006 · Cited by 138
Trowe, T., Boukouvala, S., Calkins, K., Cutler, R. E., Fong, R., Funke, R. P., Gendreau, S. B., Kim, Y. D., Miller, N., Woolfrey, J. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4367 · Cited by 136
Neoadjuvant or adjuvant chemotherapy in early breast cancer?
Montemurro, F., Nuzzolese, I., & Ponzone, R. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1746273 · Cited by 136
Utermark, T., Rao, T., Cheng, H.-L. M., Wang, Q., Lee, S., Wang, Z. C., Iglehart, J. D., Roberts, T. M., Muller, W. J., & Zhao, J. J. (2012) · Genes & Development · doi:10.1101/gad.191973.112 · Cited by 132
A review of mechanistic studies on aromatase (CYP19) and 17α-hydroxylase-17,20-lyase (CYP17)
Akhtar, M., Wright, J. N., & Lee-Robichaud, P. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.11.003 · Cited by 131
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
Montemurro, F., Valabrega, G., & Aglietta, M. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.2.257 · Cited by 131
Update on PARP Inhibitors in Breast Cancer
Zimmer, A. S., Gillard, M., Lipkowitz, S., & Lee, J. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0540-2 · Cited by 129
Finn, R., Crown, J. P., Láng, I., Boér, K., Bondarenko, I., Kulyk, S. V., Ettl, J., Patel, R., Pintér, T., Schmidt, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s1-6 · Cited by 128
Selective estrogen receptor modulators in clinical practice: a safety overview
Ellis, A., Hendrick, V. M., Williams, R., & Komm, B. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1014799 · Cited by 128
Welslau, M., Diéras, V., Sohn, J., Hurvitz, S. A., Lalla, D., Fang, L., Althaus, B., Guardino, E., & Miles, D. (2014) · Cancer · doi:10.1002/cncr.28465 · Cited by 126
Vuylsteke, P., Huizing, M. T., Petráková, K., Roylance, R. R., Laing, R. W., Chan, S. Y. T., Abell, F., Gendreau, S. B., Rooney, I. A., Apt, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw320 · Cited by 120
Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3953 · Cited by 120
Expression of the breast cancer resistance protein in breast cancer.
Faneyte, I. F., Kristel, P., Maliepaard, M., Scheffer, G. L., Scheper, R. J., Schellens, J. H. M., & van de Vijver, M. J. (2002) · PubMed · Cited by 119
Broët, P., Scholl, S. M., de la Rochefordière, A., Fourquet, A., Moreau, T., Rycke, Y. D., Asselain, B. J. R., & Pouillart, P. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006339918798 · Cited by 119
Bell, R., Brown, J. M., Parmar, M., Toi, M., Suter, T. M., Steger, G. G., Pivot, X. B., Mackey, J. R., Jackisch, C., Dent, R. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw665 · Cited by 118
Zimmer, A. S., Nichols, E. H., Cimino‐Mathews, A., Peer, C. J., Cao, L., Lee, M.-J., Kohn, E. C., Annunziata, C. M., Lipkowitz, S., Trepel, J. B., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0680-3 · Cited by 118
Ciruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 118
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
Nofech‐Mozes, S., Trudeau, M., Kahn, H. K., Dent, R. A., Rawlinson, E., Sun, P., Narod, S. A., & Hanna, W. M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0295-8 · Cited by 116
Geuijen, C. A. W., Nardis, C. D., Maussang, D., Rovers, E., Gallenne, T., Hendriks, L. J. A., Visser, T., Nijhuis, R., Logtenberg, T., de Kruif, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.003 · Cited by 115
Mittendorf, E. A., Ardavanis, A. S., Symanowski, J. T., Murray, J. L., Shumway, N. M., Litton, J. K., Hale, D. F., Perez, S. A., Anastasopoulou, E. A., Pistamaltzian, N. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw150 · Cited by 113
Mittendorf, E. A., Ardavanis, A. S., Litton, J. K., Shumway, N. M., Hale, D. F., Murray, J. L., Perez, S. A., Ponniah, S., Baxevanis, C. N., Papamichail, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11751 · Cited by 112
Dubsky, P. C., Jakesz, R., Mlineritsch, B., Pöstlberger, S., Samonigg, H., Kwasny, W., Tausch, C., Stöger, H., Haider, K., Fitzal, F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8993 · Cited by 108
Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines.
Sládek, N. E. (1999) · PubMed · Cited by 107
Saura, C., Hlauschek, D., Oliveira, M., Zardavas, D., Jallitsch-Halper, A., de la Peña, L., Nuciforo, P. G., Ballestrero, A., Dubsky, P. C., Lombard, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30334-1 · Cited by 107
Nardis, C. D., Hendriks, L. J. A., Poirier, E., Arvinte, T., Gros, P., Bakker, A. B. H., & de Kruif, J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.793497 · Cited by 105
Aldehyde Dehydrogenase-Mediated Cellular Relative Insensitivity to the Oxazaphosphorines1
Sládek, N. E. (1999) · Current Pharmaceutical Design · doi:10.2174/1381612805666230110215319 · Cited by 105
Carmichael, M. G., Benavides, L. C., Holmes, J. P., Gates, J. D., Mittendorf, E. A., Ponniah, S., & Peoples, G. E. (2009) · Cancer · doi:10.1002/cncr.24756 · Cited by 103
Mayer, I. A., Prat, A., Egle, D., Blau, S. H., Fidalgo, J. A. P., Gnant, M., Fasching, P. A., Colleoni, M. A., Wolff, A. C., Winer, E. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3160 · Cited by 100
Ng, C. M., Lum, B. L., Giménez, V. C., Kelsey, S. M., & Allison, D. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0205-x · Cited by 99
Molecular Oncology of Breast Cancer
Joshi, H. N., & Press, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00022-2 · Cited by 97
Pyrhönen, S. O., Valavaara, R., Modig, H. G., Pawlicki, M., Pieńkowski, T., Gundersen, S., Bauer, J., Westman, G., Lundgren, S., Blanco, G., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.375 · Cited by 96
Manavathi, B., Samanthapudi, V. S. K., & Gajulapalli, V. N. R. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00034 · Cited by 96
HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
Arab, A., Yazdian‐Robati, R., & Behravan, J. (2020) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-019-00566-1 · Cited by 96
Agarwal, S., Zerillo, C. A., Kolmakova, J., Christensen, J. G., Harris, L. N., Rimm, D. L., DiGiovanna, M. P., & Stern, D. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604937 · Cited by 92
Fulvestrant for hormone-sensitive metastatic breast cancer
Lee, C. I., Goodwin, A., & Wilcken, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011093.pub2 · Cited by 92
Nooka, A. K., Wang, M. L., Yee, A. J., Kaufman, J. L., Bae, J. E., Peterkin, D., Richardson, P. G. G., & Raje, N. S. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3267 · Cited by 90
The role of taxanes in the treatment of breast cancer
Nabholtz, J., & Gligorov, J. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.7.1073 · Cited by 86
Moos, P. J., & Fitzpatrick, F. A. (1998) · PubMed · Cited by 84
Sayed, R. E., Jamal, L. E., Iskandarani, S. E., Kort, J., Salam, M. A., & Assi, H. I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00510 · Cited by 82
Gershanovich, M., Garin, A. M., Baltina, D., Kurvet, A., Kangas, L., Ellmén, J., & Eastern European Study Group (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005891506092 · Cited by 78
Wilson, R. H., Evans, T. J., Middleton, M. R., Molife, L. R., Spicer, J. F., Dieras, V. C., Roxburgh, P., Giordano, H., Jaw‐Tsai, S., Goble, S. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.36 · Cited by 78
T Cell–Activating Bispecific Antibodies in Cancer Therapy
Trabolsi, A., Arumov, A., & Schatz, J. H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900496 · Cited by 77
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Conlon, N. T., Kooijman, J. J., van Gerwen, S. J. C., Mulder, W. R., Zaman, G. J. R., Diala, I., Eli, L. D., Lalani, A. S., Crown, J. P., & Collins, D. M. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01257-x · Cited by 76
Kim, T. M., Lee, K., Oh, D., Lee, J. S., Im, S., Kim, D., Han, S., Kim, Y. J., Kim, T., Kim, J. H., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2017.303 · Cited by 72
Olaparib for the treatment of breast cancer
Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1458613 · Cited by 72
Shah, M., Wedam, S. B., Cheng, J., Fiero, M. H., Xia, H., Li, F., Fan, J., Zhang, X., Yu, J., Song, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2701 · Cited by 71
Modi, S., Pusztai, L., Forero, A., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd3-14 · Cited by 67
Litton, J. K., Scoggins, M. E., Ramirez, D. L., Murthy, R. K., Whitman, G. J., Hess, K. R., Adrada, B. E., Moulder, S. L., Barcenas, C. H., Valero, V., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0052-4 · Cited by 57
Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Balmañà, J., Fasching, P. A., Hurvitz, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1007 · Cited by 54
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
Wetterskog, D., Shiu, K.-K., Chong, I. Y.-S., Meijer, T. G., Mackay, A. G., Lambros, M. B. K., Cunningham, D., Reis-Filho, J. S., Lord, C. J., & Ashworth, A. (2013) · Oncogene · doi:10.1038/onc.2013.41 · Cited by 52
Takahashi, R., Toh, U., Iwakuma, N., Takenaka, M., Otsuka, H., Furukawa, M., Fujii, T., Seki, N., Kawahara, A., Kage, M., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3685 · Cited by 50
Miller, K. D., Tong, Y., Jones, D. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1082 · Cited by 50
Role of AIB1 for Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells
Su, Q., Hu, S., Gao, H., Ma, R., Yang, Q., Pan, Z., Wang, T., & Li, F. (2008) · Oncology · doi:10.1159/000159267 · Cited by 49
Gul, A., Leyland-Jones, B., Dey, N., & De, P. K. (2018) · Europe PMC (PubMed Central) · Cited by 48
The GP2 peptide: A HER2/neu‐based breast cancer vaccine
Clive, K. S., Tyler, J., Clifton, G. T., Holmes, J. P., Ponniah, S., Peoples, G. E., & Mittendorf, E. A. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.21723 · Cited by 47
Metzger, O., Leone, J. P., Li, T., Tan‐Wasielewski, Z., Trippa, L., Barry, W. T., Younger, J., Lawler, E., Walker, L. N., Freedman, R. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.014 · Cited by 46
Clinical Development of the STn-KLH Vaccine (Theratope®)
Ibrahim, N. K., & Murray, J. L. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.s.003 · Cited by 44
Lee, G., Kim, D., Kim, H., Lee, J.-W., Chung, C.-H., Ahn, T., Lim, J. M., Kim, I., Chae, H., & Kim, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.167734 · Cited by 41
Jiang, D., Fyles, A., Nguyen, L. T., Neel, B. G., Sacher, A. G., Rottapel, R. K., Wang, B. X., Ohashi, P. S., & Sridhar, S. S. (2019) · Oncotarget · doi:10.18632/oncotarget.26893 · Cited by 40
Truncated HER2: implications for HER2-targeted therapeutics
Zagożdżon, R., Gallagher, W. M., & Crown, J. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.003 · Cited by 38
Lee, J. S., Yost, S. E., Blanchard, S., Schmolze, D. B., Yin, H. H., Pillai, R. K., Robinson, K., Tang, A., Martínez, N., Portnow, J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1202-4 · Cited by 38
Margetuximab for the treatment of HER2-positive metastatic breast cancer
Tarantino, P., Morganti, S., Uliano, J., Giugliano, F., Crimini, E., & Curigliano, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1856812 · Cited by 38
Liddil, J. D., Dorr, R. T., & Scuderi, P. (1989) · PubMed · Cited by 37
Sacituzumab govitecan: an antibody–drug conjugate
Sahota, S., & Vahdat, L. T. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1331214 · Cited by 35
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
Goel, S., Pernas, S., Tan‐Wasielewski, Z., Barry, W. T., Bardia, A., Rees, R., Andrews, C., Tahara, R. K., Trippa, L., Mayer, E. L., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.010 · Cited by 35
The Hypoxic Microenvironment of Breast Cancer Cells Promotes Resistance in Radiation Therapy
Gilreath, C., Boerma, M., Qin, Z., Hudson, M. K., & Wang, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.629422 · Cited by 35
Jhaveri, K. L., Drago, J. Z., Shah, P. D., Wang, R., Pareja, F. G., Ratzon, F., Iasonos, A. E., Patil, S. N., Rosen, N. X., Fornier, M. N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0047 · Cited by 34
Datta, J., Xu, S., Rosemblit, C., Smith, J. B., Cintolo, J. A., Powell, D. J., & Czerniecki, B. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0208 · Cited by 33
von Minckwitz, G., Rezai, M., Tesch, H., Huober, J., Gerber, B., Zahm, D.-M., Hilfrich, J., Costa, S. D., Dubsky, P. C., Blohmer, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.015 · Cited by 32
Poly-ADP-ribosylation signaling during DNA damage repair
Timinszky, G. (2015) · Frontiers in bioscience · doi:10.2741/4318 · Cited by 28
“New” molecular taxonomy in breast cancer
Hergueta‐Redondo, M., Palacios, J., Cano, A., & Moreno‐Bueno, G. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0290-x · Cited by 22
Wakeling, A. E. (1991) · Cancer treatment and research · doi:10.1007/978-1-4615-3940-7_11 · Cited by 22
Haley, B., Batra, K., Sahoo, S., Froehlich, T. W., Klemow, D., Unni, N. G., Ahn, C. W., Rodriguez, M., Hullings, M. A., & Frankel, A. E. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.03.005 · Cited by 21
Hachem, G. E., Gombos, A., & Awada, A. H. (2019) · F1000Research · doi:10.12688/f1000research.17542.1 · Cited by 20
A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation
Litton, J. K., Scoggins, M. E., Ramirez, D. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw364.10 · Cited by 18
Keegan, N. M., Furney, S. J., Walshe, J. M., Gullo, G., Kennedy, M., Smith, D., McCaffrey, J., Kelly, C. M., Egan, K., Kerr, J., et al. (2021) · Cancers · doi:10.3390/cancers13061225 · Cited by 18
Ye, Q.-L., & Zhai, Z. (2014) · Molecular Biology Reports · doi:10.1007/s11033-013-2914-7 · Cited by 14
ASCO 2019: highlights in HER2-positive metastatic breast cancer
Bartsch, R., & Bergen, E. S. (2019) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-019-00543-6 · Cited by 6
Cited by
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
Wu, S., Wu, X., Wang, Q., Chen, Z., Li, L., Chen, H., & Qi, H. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156130 · Cited by 27
A systematic review of m-health apps on managing side effects of breast cancer treatment
Wanchai, A., Anderson, E. A., & Armer, J. M. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-022-07464-x · Cited by 17
Wang, Y., Han, X., Zhang, S., Wang, L., Sun, S., Xue, C., & Yao, T. (2025) · Biopolymers · doi:10.1002/bip.70054 · Cited by 6
Metadata
- Authors
- Burguin, A., Diorio, C., & Durocher, F.
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-08-19
- Volume
- 11
- Issue
- 8
- Pages
- 808
- ISSN
- 2075-4426 (ISSN-L)
- OpenAlex
- W3194861850
- Cited by
- 488
- References
- 346
- FWCI
- 18.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.